Leading Nephrology Care Center in India Adopts Masimo Technologies Across Continuum of Care
Masimo (NASDAQ: MASI) announced today that NU Hospitals, a leading nephrology care center in India, has standardized on Masimo technologies across the continuum of care. NU Hospitals have entered into a strategic partnership with Masimo to adopt technologies in their operating rooms (ORs), intensive care units (ICUs), dialysis beds, and general wards at both of their facilities in Bangalore.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180226006532/en/
“We have been evaluating various technologies that could help our clinicians improve patient safety and at the same time help reduce the cost of care. Masimo, with its innovative range of solutions – including remote monitoring systems, depth of sedation monitoring, and noninvasive monitoring of hemoglobin and fluid responsiveness – will help us accomplish these twin objectives,” said Dr. Prasanna Venkatesh, Pediatric Urologist & Managing Director, NU Hospitals.
NU Hospitals’ ORs will be equipped with Masimo Root® Patient Monitoring and Connectivity Hubs and Radical-7® Pulse CO-Oximeters®. The monitors will include noninvasive, continuous hemoglobin monitoring (SpHb®), a Masimo rainbow® parameter, and, via Masimo Open Connect® (MOC-9®) technology, SedLine® brain function monitoring.
In critical care areas and general wards, patients at NU Hospitals will now also be continuously monitored using a variety of bedside devices such as Root with Noninvasive Blood Pressure and Temperature and Rad-97™ Pulse CO-Oximeters. Measurements will include SpHb, SET® Measure-through Motion and Low Perfusion™ pulse oximetry, vital signs such as blood pressure and temperature, and, for dialysis patients, pleth variability index (PVi®) monitoring to assist in optimizing fluid management.
The bedside devices will be connected to Masimo Patient SafetyNet™*, a supplemental remote monitoring and clinician notification system which allows patient monitoring data to be accessed from a central viewing station. When changes occur in measured values that may indicate deterioration in a patient’s condition, Patient SafetyNet automatically sends wireless alerts directly to clinicians, wherever they may be, allowing clinicians to respond quickly to patients in potential distress. In addition, Patient SafetyNet will automate the transfer of patient data, including vital signs, early warning scores (EWS), and other physiological parameters, directly to NU Hospitals’ electronic medical record (EMR) system.
Dr. Venkatesh Krishnamoorthy, Chairman and Sr. Consultant Urologist, NU Hospitals, commented, “We believe that every hospital patient should be continuously monitored. The automatic integration of data into our EMR and reduction in the manual recording of patient vitals will help us reduce transcription errors, build efficiency, and improve workflow.”
“We are excited to work with NU Hospitals and help them take better care of their patients with our advanced monitoring technologies,” said Jon Coleman, President of Worldwide Sales, Professional Services, and Medical Affairs, Masimo. “We applaud NU Hospitals for advancing the standard of care in their region.”
Bharat Monteiro, Country Manager for Masimo in India, added, “We are hopeful that more hospitals in India will adopt such advanced technologies across the continuum of care to help improve patient safety and reduce the cost of care.”
@MasimoInnovates | #Masimo
*The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,1 improve CCHD screening in newborns,2 and, when used for continuous monitoring with Masimo Patient SafetyNet™* in post-surgical wards, reduce rapid response activations and costs.3,4,5 Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,6 and is the primary pulse oximetry at 17 of the top 20 hospitals listed in the 2017-18 U.S. News and World Report Best Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), and more recently, Oxygen Reserve Index™ (ORi™), in addition to SpO2, pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect® (MOC-9®) interface, enabling other companies to augment Root with new features and measurement capabilities. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor, iSpO2 ® pulse oximeter for smartphones, and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
ORi has not received FDA 510(k) clearance and is not available for sale in the United States.
*The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.
1. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
2. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
3. Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
4. Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
5. McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
6. Estimate: Masimo data on file.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo Root®, Radical-7®, SpHb®, MOC-9®, SedLine®, Rad-97™, SET®, PVi®, and Patient SafetyNet™. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo Root, Radical-7, SpHb, MOC-9, SedLine, Rad-97, SET®, PVi, and Patient SafetyNet, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Evan Lamb, 949-396-3376
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Zephyr Endobronchial Valves Improve Breathing, Quality of Life and Activity for Severe Emphysema Patients in US Pivotal Trial22.5.2018 20:19 | Tiedote
Pulmonx® Corp. today announced positive one-year results from the U.S. LIBERATE pivotal trial of the Zephyr® Endobronchial Valve, a minimally-invasive treatment for severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522006139/en/ Zephyr Endobronchial Valves (Photo: Business Wire) “The LIBERATE Study definitively proves that Zephyr Valves offer clinically meaningful improvements in three important areas for patients – the ability to breathe better, be more active, and enjoy an improved quality of life,” said the study’s lead investigator, Gerard Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University. He continued, “All primary and secondary endpoints were met, with Zephyr Valve treatment showing significant improvement for patients across multiple measures of breathing a
Seoul Semiconductor Announces the Availability of a Series of AC LED Modules22.5.2018 19:03 | Tiedote
Seoul Semiconductor, a leading global innovator of LED products and technology, announces a comprehensive series of AC LED modules that use the company’s patented Acrich AC LED technology. The modules are offered in designs from 200 to 10,000 lumens in round, rectangular and linear formats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522006054/en/ Seoul Semiconductor Announces the Availability of a Series of AC LED Modules (Photo: Business Wire) These AC modules integrate Seoul Semiconductor’s patented Acrich AC driver technology with the company’s advanced LEDs, enabling the design of compact light fixtures with superior lighting performance, making these modules ideal for a wide range of lighting applications. “Lighting designers who are looking to significantly reduce the size, weight, and volume of their luminaire designs can select one of our standard round, rectangular, or linear AC module designs to develop a co
Medicortex Finland Announces Agreement with Pro-Lab22.5.2018 16:58 | Tiedote
Medicortex Finland Oy announces that it has entered into an agreement with a Canadian company Pro-Lab Diagnostics Inc. Pro-Lab will be responsible for the regulatory process and registration of the ProbTBI™ brain injury detection kit in Canada and UK. Following a brain injury, the diagnostic test will detect in urine and saliva a unique brain injury biomarker which has been discovered and characterized by Medicortex. The agreement gives Pro-Lab exclusive rights for sales in the UK and Canada from which Medicortex will receive royalties. The agreement between the parties is confidential and no other details about the content of the agreement are disclosed. Pro-Lab will be responsible for the clinical validation of the kit prior to the commercial launch in the territories. In addition to the licensing agreement, the parties intend to initiate a development collaboration, the details of which are being discussed currently. “We are very proud that Pro-Lab Diagnostics has chosen to cooperat
ResMed Studies Show Remote Monitoring and Automated Resupply Improve Adherence to PAP Therapy22.5.2018 15:55 | Tiedote
Remote patient monitoring and resupply programs have been shown to improve patient adherence to positive airway pressure (PAP) therapy, according to two separate studies presented by ResMed (NYSE: RMD, ASX: RMD) this week at the ATS 2018 International Conference. Remote monitoring boosts compliance In the first study, medXcloud, a ResMed-assembled group of healthcare key opinion leaders, examined de-identified data of more than 2.6 million U.S. PAP users from ResMed’s world-leading remote monitoring network, AirView. Using this big data approach, researchers observed excellent adherence among patients initiating PAP therapy: 75 percent achieved the CMS compliance threshold.* This rate compares very favorably with that of non-cloud-connected PAP therapy and other chronic medical therapies – both around 50 percent. Plus, the large sample suggests that the findings are generalizable and likely to reflect real-world clinical care. Resupply program boosts long-term compliance In a separate
Asuragen to Launch the AmplideX® PCR/CE DMPK Kit and Present Growing Genetic Testing Portfolio at 2018 European Society of Human Genetics (ESHG) Conference22.5.2018 15:00 | Tiedote
Asuragen, Inc., a molecular diagnostics company delivering high-quality, easy to use products for complex testing in genetics and oncology, today announced the launch of the AmplideX® PCR/CE DMPK Kit* to simplify analysis of repeat expansions within the DMPK gene, which is implicated in myotonic dystrophy type I (DM1), also known as Steinert’s disease. DM1 is an inherited form of muscular dystrophy that affects the muscles as well as multiple other organ systems, and its severity is largely determined by the size of the CTG trinucleotide repeat expansion within the DMPK gene. These expansions commonly extend beyond a thousand CTG repeats and therefore have required the use of cumbersome Southern blot technology to estimate their size. “The AmplideX DMPK Kit represented a significant improvement over our existing process for analyzing large DMPK expansions,” said Doctor Sophie Rondeau, PharmD, PhD, and Professor Jean-Paul Bonnefont, MD, PhD, of the Necker-Enfants Malades Hospital in Par
Phil Brakewell Set to Lead WilsonHCG's Executive Search Efforts Across EMEA; Forbes Ranks WilsonHCG Among Best Executive Recruiting Firms22.5.2018 15:00 | Tiedote
WilsonHCG, global leader and premium provider of innovative talent solutions, further expands its Executive Search division with the appointment of Director Phil Brakewell. Phil, who brings more than 14 years of talent acquisition leadership experience and most recently served as Head of Executive Search for ResourceBank, will be responsible for leading WilsonHCG’s efforts in the EMEA region. Prior to joining ResourceBank, Phil held consultant and resourcing leadership positions at Hitchenor Wakeford and The Caudwell Group – where he was responsible for developing the business internationally and drove innovative search solutions on behalf of a diverse range of clients. “WilsonHCG’s reputation speaks for itself,” said Phil. “WilsonHCG tailors its key service offerings – including Executive Search – to suit individual client needs, and I am thrilled to be part of such a dedicated, innovative team. The new Director position, covering EMEA, demonstrates our commitment to both Executive Se
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme